21 June 2012, Munich – Dr Manfred Baier joined Ascenion’s Advisory Board on 1 June this year. The company thereby gains an experienced industry manager with special expertise in the development and marketing of innovative diagnostics.
“We extend a warm welcome to Dr Baier,” said Dr Christian Stein, CEO of Ascenion. “His long-standing experience will be highly valuable in the commercial exploitation of our partners’ projects. The development of novel therapies increasingly depends on the availability of complementary diagnostics that allow the clinical development and utilization of new therapies to be tailored to different patient groups.”
Dr Manfred Baier has worked more than 30 years for Roche Diagnostics, most recently as Head of the globally operating business unit Roche Applied Science, to which the US genomics companies 454 Life Sciences and NimbleGen belong. He previously held several leadership positions in the concern, including General Manager for Sales, Germany and Head of various business areas. In addition, Dr Manfred Baier is a member of the Board of Directors or Advisory Board of numerous life-science companies in Germany, Sweden and the United Kingdom. Dr Baier holds a degree in chemistry and gained his PhD in biochemistry at the University of Stuttgart under the supervision of Prof. Pfleiderer.
“Ascenion has access to a fascinating range of technologies and know-how“, said Dr Baier. “I’m very much looking forward to working with the Ascenion team in order to release this potential into medical applications and develop these for the market.”
Ascenion is the exclusive technology transfer partner of numerous life-science institutes in the Helmholtz and Leibniz Associations, Hannover Medical School (MHH), TWINCORE and the Mouse Genetics Cologne Foundation.
About Ascenion GmbH
Ascenion GmbH is an IP asset management company with particular expertise in the life sciences. Ascenion advises and supports public research institutions with regard to the protection and exploitation of their intellectual property (patents, know-how, materials), and initiates and mediates license agreements between research institutions and industry. The company places particular emphasis on coaching company founders and on active equity management. Ascenion was founded in 2001 as a 100% subsidiary of the LifeScience-Foundation for the Promotion of Science and Research and has since acquired 23 research institutes in the Helmholtz and Leibniz Associations, together with the Hannover Medical School, the research institute Twincore and the Mouse Genetics Cologne Foundation as exclusive partners. Ascenion currently markets around 750 technologies on behalf of these institutes, and closes an average of about 80 agreements between research and industry per year. The team has also coached numerous spin-offs through their foundation and early growth and Ascenion holds equity in 24 of these companies. Ascenion’s headquarters are in Munich, with further offices in Berlin, Braunschweig, Hamburg, Hanover and Neuherberg. Further information at <link http: www.ascenion.de external-link-new-window>www.ascenion.de
